

1 **β3-Adrenergic receptor-dependent modulation of the medium afterhyperpolarization**
2 **in rat hippocampal CA1 pyramidal neurons**

3

4 **Authors:** Timothy W. Church^{1*}, Jon T. Brown², Neil V. Marrion¹

5 ¹School of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol, United
6 Kingdom, BS8 1TD, UK.

7 ²University of Exeter Medical School, Hatherly Building, Exeter, United Kingdom, EX4 4QJ,
8 UK.

9 *Present address: Department of Neuroscience, Physiology & Pharmacology, University
10 College London, London, UK, WC1E 6BT

11

12 **Author's contributions:** TWC conducted the experiments, analysed the data and wrote the
13 first draft of the manuscript. JTB provided analysis software and help plan early
14 experiments. NVM supervised the project, directed experiments and wrote the paper.

15

16 **Running Head:** β3-adrenergic receptor-mediated suppression of the medium AHP

17

18 **Correspondence:** Professor N.V. Marrion as above.

19 Tel: +441173311401

20 Email: N.V.Marrion@bristol.ac.uk

21

22

23 Number of pages: 29

24 Number of figures: 5

25 Number of tables: 0

26 Number of words for abstract: 250

27

28 **Abstract**

29 Action potential firing in hippocampal pyramidal neurons is regulated by generation of an
30 afterhyperpolarization (AHP). Three phases of AHP are recognised, with the fast AHP
31 regulating action potential firing at the onset of a burst, and the medium and slow AHPs
32 suppressing action potential firing over 100s of milliseconds and seconds respectively.
33 Activation of β -adrenergic receptors suppresses the slow AHP by a protein kinase A-
34 dependent pathway. However, little is known regarding modulation of the medium AHP.
35 Application of the selective β -adrenergic receptor agonist isoproterenol suppressed both the
36 medium and slow AHPs evoked in rat CA1 hippocampal pyramidal neurons recorded from
37 slices maintained in organotypic culture. Suppression of the slow AHP was mimicked by
38 intracellular application of cAMP, with the suppression of the medium AHP by isoproterenol
39 still being evident in cAMP-dialysed cells. Suppression of both the medium and slow AHPs
40 was antagonised by the β -adrenergic receptor antagonist propranolol. The effect of
41 isoproterenol to suppress the medium AHP was mimicked by two β_3 -adrenergic receptor
42 agonists: BRL37344 and SR58611A. The medium AHP was mediated by activation of SK
43 and deactivation of H channels at the resting membrane potential. Suppression of the
44 medium AHP by isoproterenol was reduced by pre-treating cells with the H-channel blocker
45 ZD7288. These data suggest that activation of β_3 -adrenergic receptors inhibits H-channels,
46 which suppresses the medium AHP in CA1 hippocampal neurons by utilising a pathway that
47 is independent of a rise of intracellular cAMP. This finding highlights a potential new target
48 in modulating H-channel activity, and thereby neuronal excitability.

49

50

51 **New & Noteworthy**

52 The noradrenergic input into the hippocampus is involved in modulating long-term synaptic
53 plasticity and is implicated in learning and memory. We demonstrate that activation of
54 functional β_3 -adrenergic receptors suppresses the medium AHP in hippocampal pyramidal

55 neurons. This finding provides an additional mechanism to increase action potential firing
56 frequency, where neuronal excitability is likely to be crucial in cognition and memory.

57

58

59 **Introduction**

60 Action potential firing is regulated by the generation of an afterhyperpolarization (AHP)
61 following a single or train of action potentials (Alger and Nicoll, 1980; Madison and Nicoll,
62 1984; Alger and Williamson, 1988; Storm, 1990; Gu et al., 2005). The AHP influences both
63 the frequency and patterning of neuronal firing. An increase in action potential firing is
64 observed after pharmacologically inhibiting AHPs (Lancaster and Adams, 1986; Pedarzani
65 and Storm, 1993; Stocker et al., 1999; Gu et al., 2005; Tombaugh et al., 2005), while a
66 decrease in action potential firing results from potentiation of the AHP (Pedarzani et al.,
67 2005; Gu et al., 2008). Hippocampal CA1 pyramidal neurons exhibit an AHP that has three
68 main components, based on both kinetics and pharmacology. The fast AHP results from
69 activation of BK channels and regulates firing at the onset of a burst (Storm, 1989). In
70 contrast, the medium AHP regulates firing 50-200 ms after a burst of action potentials and
71 the slow AHP affects firing over many seconds following a burst of action potentials (Storm,
72 1989; Stocker, 2004; Gu et al., 2005; Vatanparast and Janahmadi, 2009; Chen et al., 2014).
73 The medium AHP in hippocampal CA1 neurons is mediated by 3 different ion channel
74 subtypes, small-conductance, calcium-activated K⁺ (SK) channels (Stocker et al., 1999;
75 Bond et al., 2004; Church et al., 2014), voltage-dependent M-channels (K_V7/KCNQ) (Gu et
76 al., 2005; Tzingounis et al., 2007), and the hyperpolarization-activated cyclic nucleotide-
77 gated (HCN) channel (Gu et al., 2005; Kaczorowski, 2011). There is still controversy
78 regarding the channel(s) underlying the slow AHP in hippocampal pyramidal neurons, with
79 the intermediate-conductance Ca²⁺-dependent K⁺ (IK) channel (King et al., 2015; Turner et
80 al., 2016), voltage-dependent K_V7 channel (Tzingounis et al., 2007), and ATPase-Na⁺/K⁺
81 pump (Gulledge et al., 2013) all been proposed to mediate this slow afterpotential.

82

83 The slow AHP is unusual in being suppressed by different monoamines, such as
84 noradrenaline (Madison and Nicoll, 1982; Pedarzani and Storm, 1993), dopamine (Malenka
85 and Nicoll, 1986), serotonin (Pedarzani and Storm, 1993), and histamine (Haas and Greene,
86 1986; Pedarzani and Storm, 1993). Monoamine neurotransmitters suppress the slow AHP
87 by the canonical $G\alpha_s$ G-protein pathway, which results in the formation of cAMP by the
88 stimulation of adenylate cyclase and subsequent activation of protein kinase A (Pedarzani
89 and Storm, 1993). For example, suppression of the slow AHP by noradrenaline is
90 antagonised by the β -adrenergic receptor (β AR) antagonist propranolol (Madison and Nicoll,
91 1982). Immunohistochemistry has identified that β 1- and β 2-adrenergic receptors are
92 expressed throughout the hippocampus, with both subtypes being located in both the soma
93 and dendrites of CA1 pyramidal neurons (Guo and Li, 2007; Cox et al., 2008). β 3-
94 adrenergic receptor mRNA has also been identified in the rodent and human hippocampus
95 (Rodriguez et al., 1995; Evans et al., 1996), albeit a lower expression than seen for β 1 and
96 β 2 receptors (Evans et al., 1996; Claustre et al., 2008). The functional role of the β 3AR in
97 the hippocampus is unclear; however β 3AR agonists demonstrate anti-depressant and
98 anxiolytic effects in rodents (Simiand et al., 1992; Consoli et al., 2007; Claustre et al., 2008;
99 Tamburella et al., 2010; Tanyeri et al., 2013).

100

101 In this study we show that non-selective pharmacological activation of β -adrenergic
102 receptors suppressed both the medium and slow AHPs, an effect antagonised by
103 propranolol. The effect of β receptor activation on the slow AHP was occluded by
104 intracellular dialysis of cAMP, whereas suppression of medium AHP persisted. The medium
105 AHP was generated by SK and HCN channels in CA1 neurons held at -75 mV, with the
106 effect of isoproterenol reduced by prior block of HCN-mediated H-current. Suppression of
107 the medium AHP was mimicked by two different selective β 3-adrenergic receptor agonists.
108 These data suggest that the activation of β 3-adrenergic receptors suppresses the medium
109 AHP by inhibiting HCN channel activity using a cAMP-independent pathway. These findings

110 illustrate an additional mechanism to modulate hippocampal neuron excitability utilising a
111 novel pathway.
112

113 **Materials and Methods**

114 *Organotypic hippocampal slice cultures.* Organotypic slice cultures from the hippocampus
115 were prepared from 18 to 20-day-old male Wistar rats as described previously (Stoppini et
116 al., 1991). Rats were killed by cervical dislocation in accordance with Schedule 1 of the UK
117 home office guidelines set out in the Animals (Scientific Procedures) Act 1986. All
118 procedures were carried out in accordance with the UK Animal (Scientific Procedures) Act,
119 1986, and EU Directive 2010/63/EU. All experimental procedures were reviewed by the
120 University of Bristol Ethical Review Group (reference: UB/12/006). Brains were removed
121 and horizontal brain slices (300 μ M) were cut in ice-cold (\sim 4 $^{\circ}$ C) sucrose-based cutting
122 solution containing (in mM): 189 sucrose, 10 D-glucose, 26 NaHCO_3 , 3 KCL, 5
123 $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 0.1 CaCl_2 , 1.25 NaH_2PO_4 , saturated with 95% O_2 and 5% CO_2 using a
124 VT1000 S vibrating blade microtome (Leica Microsystems Ltd, Milton Keynes, UK). After
125 sectioning, hippocampal slices were transferred to a storage chamber filled with artificial
126 cerebrospinal fluid (aCSF) containing (in mM): 124 NaCl, 3 KCl, 24 NaHCO_3 , 1.25
127 $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$, 1 $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 2 CaCl_2 , 10 D-glucose saturated with 95% O_2 and 5% CO_2 .
128 Under aseptic conditions, slices were washed twice with culture media containing Minimum
129 Essential Medium (Gibco) supplemented with (in mM): 50 NaHCO_3 , 75 HEPES, 0.437
130 glutamine, 0.625 CaCl_2 , 1.25 $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 0.425 ascorbic acid, 32 D-glucose, with 12.5%
131 heat-inactivated horse serum, 1 mg/L insulin, and 100 units/ml penicillin with 100 μ g/ml
132 streptomycin (pH 7.28 with NaOH, osmolarity \sim 320 mOsm). Slices were washed a further
133 two times in culture media without supplemented penicillin/streptomycin. Slices were
134 cultured on a porous (0.4 μ M) membrane (Millicell inserts, Millipore) and maintained at 37 $^{\circ}$ C
135 in 5% CO_2 for 3 days before slices were used for electrophysiological recordings. The
136 characteristics of the medium and slow AHPs recorded in CA1 pyramidal neurons from
137 slices maintained in short-term organotypic culture were comparable with those reported in
138 CA1 neurons from acute hippocampal slice preparations taken from similar aged animals
139 (Maccaferri et al., 1993; Stocker et al., 1999; Lancaster et al., 2001; Kaczorowski et al.,
140 2007; Kaczorowski, 2011).

141

142 *Electrophysiology.* Slices were continuously perfused (2-3 ml/min) with aCSF supplemented
143 with NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione) (10 μ M) to
144 inhibit spontaneous AMPA receptor-mediated excitatory post-synaptic currents. The aCSF
145 was continuously oxygenated and temperature was maintained at $\sim 33^{\circ}\text{C}$ using an HPT-2
146 inline heater (Scientifica, UK). Whole-cell current-clamp recordings were made from visually
147 identified pyramidal neurones from the CA1 region of the hippocampus using an infrared-
148 light emitting diode mounted on an Axioskop2 microscope (Carl Zeiss). Fire-polished
149 electrodes (3-5 M Ω) were fabricated from borosilicate glass (1.5 mm O.D., 0.86 mm I.D.)
150 containing (in mM): 125 KMeSO₄, 10 KCl, 10 NaCl, 20 HEPES, 2 MgATP, 0.3 Na₂GTP, 0.2
151 EGTA, pH 7.3, osmolarity 280-285 mOsm. A liquid junction potential error was
152 experimentally measured (+13 mV) and was compensated for during recording. The
153 membrane voltage for all recordings was recorded in the bridge-balance mode of the
154 MultiClamp 700A amplifier (Molecular Devices, CA, USA). Voltage responses were filtered
155 at 1.2 kHz (eight-pole low-pass Bessel filter) and sampled at 5 kHz using Pulse (HEKA
156 Electronics, Lambrecht, Germany).

157

158 *Data analysis.* AHPs were elicited by evoking a train of 15 action potentials by brief (2 ms) 2
159 nA somatic current injections delivered at 50 Hz. Any cell that did not fire the correct number
160 of APs was discarded. Analysis of the medium AHP and slow AHPs were carried out using
161 custom-written MatLab scripts (The MathWorks Company). The mAHP were measured as
162 the peak negative membrane deflection between 0 to 100 ms after the cessation of the last
163 AP action potential fired. The slow AHP was measured 1 second after the last AP action
164 potential was fired. The overlapping kinetic profiles of the medium AHP and slow AHP was
165 minimized by measuring the AHP components within these time points. Finally, the
166 hyperpolarization induced H-current-mediated depolarizing sag was measured as the
167 percentage difference between the peak negative deflection and the membrane voltage

168 once at steady state in response to a hyperpolarizing current injection (100 pA amplitude,
169 500 ms duration) (Tamagnini et al., 2015).

170

171 Cell input resistance was determined from a -100 pA current pulse (500 ms) delivered 1
172 second before a train of action potentials to generate AHPs. The non-conductive anion
173 methylsulphate (MeSO_4) is associated with a time-dependent rise in input resistance (Zhang
174 et al., 1994; Velumian et al., 1997; Kaczorowski et al., 2007). We observed that the cell
175 input resistance rose by $13.4 \pm 4.3\%$ during a 5-minute baseline recording period ($105.8 \pm$
176 5.2 vs 121.0 ± 12.9 M Ω ; $n = 6$; $t = -3.0$, $P = 0.03$; paired two-tailed Student's t -test). During
177 this same 5-minute baseline recording, the medium AHP amplitude did not change ($-4.4 \pm$
178 0.3 vs -4.5 ± 0.2 mV; $t = 0.2$, $P = 0.84$, paired two-tailed Student's t -test), while the slow AHP
179 increased by $25.3 \pm 21.6\%$ (-2.2 ± 0.2 vs -2.6 ± 0.2 mV; $t_{(5)} = 1.0$, $P = 0.4$). All recordings
180 used cells with a stable resting membrane potential more negative than -60 mV.

181

182 *Drugs.* All salts were purchased from Sigma-Aldrich except HEPES, which was obtained
183 from Merck Serono (Fletham, UK). Isoproterenol and propranolol were purchased from
184 Sigma-Aldrich, whereas NBQX, ZD7288, XE991, BRL37344, SR58611A and apamin were
185 purchased from Tocris Biosciences (Bristol, UK). NBQX and ZD7288 were both prepared as
186 stock solutions in dimethylsulfoxide (DMSO) and diluted in aCSF when required. BRL37344,
187 SR58611A, apamin, isoproterenol and propranolol were prepared as stock solutions in
188 water. All drugs were prepared as 1000x stock solutions and stored at -20 °C until required,
189 except for isoproterenol and propranolol which were prepared daily. All drugs were applied
190 to the perfusion system.

191

192 *Statistics.* Statistical analysis was performed using SPSS (v21, IBM) and representative
193 traces were drawn using Origin 9 (Microcal Software). All data is presented as mean \pm
194 SEM. Paired two-tailed Student's t -tests were used to compare the means between control
195 and drug treatment groups. A repeated measures ANOVA was used to compare AHP

196 amplitudes after the addition of two or more drugs. Fisher's least significant difference (LSD)
197 post-hoc tests were performed to assess between-drug treatment differences.
198

199 **Results**

200 **The β -adrenergic receptor agonist isoproterenol inhibits both the medium and slow**
201 **AHPs**

202 AHPs were evoked from a membrane potential of -75 mV by a train of 15 action potentials
203 evoked by brief (2 ms) current injections (2 nA) fired at 50 Hz (Fig. 1A). As previously
204 reported (Pedarzani and Storm, 1993), bath application of the selective β -adrenergic
205 receptor agonist isoproterenol (1 μ M; $n = 7$) reduced the amplitude of the slow AHP by 71.6
206 $\pm 20.6\%$ (Fig. 1A, D & F) (-1.1 ± 0.2 vs 0.4 ± 0.2 ; $t = -3.8$, $P = 0.009$, paired two-tailed
207 Student's t -test). We are the first to report that activation of β -adrenergic receptors also
208 reduced the amplitude of the medium AHP, with the peak medium AHP amplitude being
209 reduced by $37.6 \pm 6.5\%$ (Fig. 1A-B, C & E) (-3.1 ± 0.4 vs -1.9 ± 0.3 mV; $t = -4.6$, $P = 0.004$,
210 paired two-tailed Student's t -test). Both responses were antagonised by the selective
211 competitive β -adrenergic receptor antagonist, propranolol. Pre-treatment of slices with
212 propranolol (10 μ M) for 10 minutes prevented the effect of isoproterenol in suppressing
213 either the medium (Fig. 1G) (control -5.2 ± 1.3 mV, propranolol -5.6 ± 1.7 mV, propranolol +
214 isoproterenol -5.4 ± 1.8 mV; overall effect of drugs $F_{(2,6)} = 0.2$, $P = 0.81$, repeated measures
215 ANOVA) or slow (Fig. 1H) (control -3.6 ± 1.5 mV, propranolol -4.1 ± 1.8 mV, propranolol +
216 isoproterenol -4.4 ± 2.0 mV; $n = 4$; overall effect of drugs $F_{(2,6)} = 1.4$, $P = 0.33$, repeated
217 measures ANOVA) AHPs. These data indicate that activation of β -adrenergic receptors
218 suppresses both the medium and slow AHPs.

219

220 **β -adrenergic receptor-mediated modulation of the medium AHP is independent of a**
221 **rise of intracellular cAMP**

222 The time-course of the medium and slow AHPs overlap (Stocker et al., 1999; Gerlach et al.,
223 2004), making it difficult to resolve whether each AHP component can be modulated
224 independently. The slow AHP was suppressed by inclusion of cAMP (1 mM) in the whole-
225 cell electrode solution (Pedarzani and Storm, 1993) (non-cAMP, $n = 80$, cAMP, $n = 20$;
226 overall effect of cAMP $F_{(1,98)} = 13.4$, $P = 0.0004$; two-way repeated measures ANOVA. Fig.

227 2A), and was observed together with a significant reduction in the amplitude of the medium
228 AHP (Fig. 2B) ($n = 80$, cAMP, $n = 20$; overall effect of cAMP $F_{(1, 98)} = 12.6$, $P = 0.0006$; two-
229 way repeated measures ANOVA). It is most likely that these observations reflect an overlap
230 in time-course. Therefore, it is crucial to determine whether the medium AHP is sensitive to
231 isoproterenol in neurons dialyzed with cAMP. Addition of isoproterenol ($1 \mu\text{M}$) to neurons
232 dialyzed with cAMP (1 mM) reduced the amplitude of the medium AHP by $58.2 \pm 8.2\%$ (Fig.
233 2C, D, E & F) (-1.9 ± 0.3 vs $-0.9 \pm 0.3 \text{ mV}$; $n = 5$; $t = -8$, $P = 0.001$, paired two-tailed
234 Student's t -test). The magnitude of reduction of the mAHP by isoproterenol was the same
235 between control and cells dialyzed with cAMP ($t = 1.9$, $p = 0.073$). These data demonstrate
236 that suppression of the medium AHP by isoproterenol is not the result of an overlapping
237 time-course of afterpotentials and suppression of the slow AHP. It is apparent that the effect
238 of isoproterenol is mediated by β -adrenergic receptors and that suppression of the medium
239 AHP is independent of a rise of intracellular cAMP.

240

241 **Blocking HCN channels with ZD7288 reduced suppression of the medium AHP by** 242 **isoproterenol**

243 The medium AHP in hippocampal CA1 pyramidal neurons is proposed to be mediated by
244 activation of SK and deactivation of HCN channels at hyperpolarized voltages (Gu et al.,
245 2005; Kaczorowski, 2011; Church et al., 2015). This was confirmed by observing that
246 addition of the HCN channel blocker ZD7288 ($1 \mu\text{M}$) blocked the medium AHP by $52.2 \pm$
247 16.5% ($P = 0.047$) (Fig. 3A-D), with the sequential addition of the SK channel inhibitor
248 apamin (100 nM) blocking the remaining afterpotential by a further $43.3 \pm 11.8\%$ ($P = 0.054$)
249 (Fig. 3A-D) (control $-4.3 \pm 1.5 \text{ mV}$, ZD7288 $-2.0 \pm 0.7 \text{ mV}$, ZD7288 + apamin $-0.1 \pm 0.3 \text{ mV}$;
250 $n = 4$; overall effect of drugs $F_{(2, 6)} = 19.8$, $P = 0.002$, repeated measures ANOVA). No effect
251 of either ZD7288 or apamin on the slow AHP was observed (Fig. 3D) (control $-1.8 \pm 0.1 \text{ mV}$,
252 ZD7288 $-2.4 \pm 0.2 \text{ mV}$, ZD7288 + apamin $-2.2 \pm 0.4 \text{ mV}$; $n = 4$; overall effect of drugs $F_{(2, 6)} =$
253 1.9 , $P = 0.23$, repeated measures ANOVA).

254

255 These data pose the question of which channel subtype(s) is modulated by β -adrenergic
256 receptor activation. Blocking HCN channels with ZD7288 (1 μ M) reduced the medium AHP
257 by $74.5 \pm 14.5\%$ ($P = 0.06$) (Fig. 4Ai-iv) and reduced the effect of subsequent concomitant
258 addition of isoproterenol (1 μ M) (Fig. 4Ai-iv) (control -4.4 ± 0.5 mV, ZD7288 -1.0 ± 0.5 mV,
259 ZD7288 + isoproterenol -0.8 ± 0.6 mV; $n = 3$; overall effect of drugs $F_{(2, 4)} = 15.1$, $P = 0.014$;
260 main effect of ZD7288 $P = 0.06$; main effect of ZD7288 + isoproterenol $P = 0.21$; repeated
261 measures ANOVA). In contrast, application of apamin (100 nM) blocked the medium AHP
262 by $32.7 \pm 6.3\%$ ($P = 0.007$) (Fig. 4Bi-iv), with the concomitant addition of isoproterenol (1
263 μ M) still suppressing the remaining medium AHP by $37.2 \pm 8.4\%$ (Fig. 4Bi-iv) ($P = 0.003$)
264 (control -4.9 ± 0.8 mV; apamin -3.4 ± 0.7 mV; apamin + isoproterenol -1.5 ± 0.6 mV; $n = 4$;
265 overall effect of drugs $F_{(2, 6)} = 22.8$, $P = 0.002$; repeated measures ANOVA). Activation of
266 HCN channels by membrane hyperpolarization results in a depolarizing sag in the
267 electrotonic potential. This sag is reduced by HCN channel blockers, such as ZD7288 (Day
268 et al., 2005; Thuault et al., 2013). Application of a sub-maximal concentration of ZD7288 (1
269 μ M) reduced the sag by 96%, reducing the sag from contributing $29.6 \pm 2.1\%$ of the
270 electrotonic potential to contributing $2.1 \pm 1.2\%$ ($t = 13.8$; $p < 0.0001$, paired two-tailed
271 Student's t -test). Application of isoproterenol (1 μ M) resulted in a $27.6 \pm 8.8\%$ reduction in
272 depolarizing sag (25.6 ± 1 vs $18.6 \pm 2.4\%$; $n = 7$; $t = 3.3$ $P = 0.02$; paired two-tailed Student's
273 t -test). These data strongly suggest that suppression of the medium AHP by isoproterenol is
274 mediated by modulating HCN channel activity in hippocampal CA1 pyramidal neurons.

275

276 **The selective β 3-adrenergic receptor agonists BRL37344 and SR58611A suppress the** 277 **medium AHP**

278 Low levels of β 3-adrenergic receptor mRNA is expressed in the hippocampus of mouse and
279 rat (Evans et al., 1996; Claustre et al., 2008). β 3-adrenergic receptors display a low binding
280 affinity for propranolol (Hoffmann et al., 2004), and we observed that pre-treating
281 hippocampal slices with 1 μ M propranolol ($n = 8$) failed to antagonise the effect of
282 isoproterenol on the medium AHP (data not shown). The β 3-adrenergic receptor selective

283 agonist BRL37344 (10 μ M; $n = 4$) (Hoffmann et al., 2004) suppressed the medium AHP by
284 $42.2 \pm 9.3\%$ (Fig. 5Ai-ii) (-3 ± 0.4 vs -1.8 ± 0.5 mV; $t = -4.2$, $P = 0.025$, paired two-tailed
285 Student's t -test). Application of a second β 3-adrenergic receptor selective agonist
286 SR58611A (10 μ M) (Bianchetti and Manara, 1990; Simiand et al., 1992) also suppressed the
287 medium AHP by $33.7 \pm 6.5\%$ (Fig. 5Bi-ii) (-3.1 ± 0.4 vs -2.1 ± 0.4 mV; $n = 7$; $t = -3.6$, $P =$
288 0.012). The magnitude of suppression of the medium AHP by BRL37344 and SR58611A
289 were not significantly different ($t = -1.1$, $P = 0.312$; unpaired two-tailed Student's t -test). In
290 contrast to BRL37344 which exhibited no significant reduction on the H-current-mediated
291 depolarizing sag (25.8 ± 2.4 vs $18.1 \pm 2.6\%$; $n = 4$; $t = 1.9$; $P = 0.151$; paired two-tailed
292 Student's t -test), SR58611A reduced the H-current-mediated depolarizing sag by 17.5%
293 (23.2 ± 3.0 vs $19.0 \pm 2.9\%$; $n = 10$; $t = 3.0$; $P = 0.014$; paired two-tailed Student's t -test).
294 BRL37344 (10 μ M) failed to affect the medium AHP when applied in the presence of
295 propranolol (10 μ M) (Fig. 5C & D) (control -4.7 ± 0.9 mV, propranolol -5.0 ± 1.5 mV,
296 propranolol + BRL37344 -4.9 ± 1.6 mV; $F_{(2,4)} = 0.1$, $P = 0.93$, repeated measures ANOVA; n
297 = 3). These findings indicate the presence of functional β 3-adrenergic receptors in
298 hippocampal CA1 pyramidal neurons that selectively suppress the medium AHP, and not the
299 slow AHP. Finally, BRL37344 (10 μ M) suppressed the medium AHP by $37.8 \pm 8.2\%$ in CA1
300 pyramidal neurons dialyzed with cAMP (1 mM) (Fig. 5E & F) (-2.9 ± 0.2 vs -1.8 ± 0.2 mV; $t =$
301 -4.3 , $P = 0.003$; $n = 9$, paired two-tailed Student's t -test). There was no significant difference
302 in the magnitude of block produced by BRL37344 (10 μ M) in cAMP-dialysed cells (1 μ M)
303 compared with non-cAMP dialysed neurons (0 mM cAMP $42.2 \pm 9.3\%$; 1 mM cAMP $37.8 \pm$
304 8.2% $t = 0.3$, $P = 0.76$). These data confirm that activation of β 3-adrenergic receptors
305 suppresses the medium AHP by a cAMP-independent signalling pathway.

306

307 **Discussion**

308 The slow AHP is unusual in being a potassium current subject to modulation by GPCR
309 activation (Pedarzani and Storm, 1993). This slow afterpotential is sensitive to activation of
310 GPCRs that are coupled via G_s to activation of adenylate cyclase, a rise of intracellular
311 cAMP and subsequent activation of protein kinase A (Pedarzani and Storm, 1993). We have
312 confirmed the sensitivity of the slow AHP to activation of β -adrenergic receptors and a rise of
313 intracellular cAMP. In contrast, evidence of the medium AHP being modulated by
314 metabotropic receptor activation in hippocampal pyramidal cells is lacking. It was noted that
315 the medium AHP was reduced when the slow AHP was suppressed by forskolin, but this
316 was suggested to result from an overlap of the time-courses of the two components of the
317 AHP (Gu et al., 2005). We have carefully separated the amplitudes of the two
318 afterpotentials, by plotting of the AHP time-course on a log time base (Figure 1B). In
319 addition, we have presented data of the reduction of the medium AHP by isoproterenol in
320 cells where the slow AHP has been abolished by intracellular dialysis of cAMP (Figure 2C-
321 F). These data confirm that the medium AHP is a substrate for modulation and that
322 suppression of the afterpotential is not mediated by a rise of intracellular cAMP. The effect
323 of isoproterenol was mimicked by two selective β_3 -adrenergic receptor agonists, BRL37344
324 and SR58611A. The mRNA encoding the β_3 -adrenergic receptor has been detected in
325 various brain regions including the hippocampus in rat, mouse and humans (Rodriguez et
326 al., 1995; Evans et al., 1996; Claustre et al., 2008). The precise role of the β_3 -adrenergic
327 receptor in brain is unclear, but BRL37344 and SR58611A possess anti-depressant and
328 anxiolytic-like effects in rodents (Simiand et al., 1992; Claustre et al., 2008; Stemmelin et al.,
329 2008; Tanyeri et al., 2013). Activation of hippocampal β_3 -adrenergic receptors by
330 norepinephrine and isoproterenol mediate an increase in hippocampal neural precursor
331 activity by enhancing the proliferation of multipotent neuronal stem (Jhaveri et al., 2010).

332

333 BRL37344 displays a 90-fold and 20-fold higher selectivity towards rat β_3 -adrenergic
334 receptors compared with β_1 - and β_2 -adrenergic receptors respectively (Hoffmann et al.,

335 2004), whereas SR58611A exhibits a 280-fold and 140-fold higher selectivity for rat β 3-
336 adrenergic receptors compared with β 1- and β 2-adrenergic receptors respectively (Gauthier
337 et al., 1996; Stemmelin et al., 2008). The selectivity of these agonists is better than that
338 reported for available β 3-adrenergic receptor antagonists. For example, L-748337 displays
339 less than a 20-fold selectivity and L-748328 exhibits only a 45-fold selectivity for β 3-
340 adrenergic receptors over β 2-adrenergic receptors (Candelore et al. 1999). In addition, SR
341 59230A displays only a 10-fold selectivity for β 3-adrenergic receptors over β 1- and β 2-
342 adrenergic receptors (Manara et al., 1996). In absence of attempting full concentration-
343 response relationships in the absence and presence of increasing concentrations of
344 antagonist(s), we elected to use β 3-adrenergic receptor-selective agonists to elucidate the
345 role of these receptors in hippocampal neurons. A very small reduction in the amplitude of
346 the slow AHP was seen in the presence of BRL37344, but not when SR58611A was applied
347 (Figure 5Aii & 5Bii), which might result from the low affinity binding of BRL37344 to β 1- and
348 β 2-adrenergic receptors. These findings indicate that activation of β 3-adrenergic receptors
349 suppresses the medium and not the slow AHP in hippocampal CA1 pyramidal neurons.

350

351 **SK and HCN channels underlie the medium AHP in CA1 pyramidal neurons at** 352 **hyperpolarized potentials**

353 There is some controversy regarding the channel subtypes that contribute to the medium
354 AHP, with activation of SK (Stocker et al. 1999) and deactivation of HCN channels (Gu et al.
355 2005) being proposed to underlie the afterpotential at hyperpolarized potentials. The role of
356 SK channel activation is unclear, as it has been suggested only to result from non-
357 physiological activation protocols used in voltage clamp (Gu et al. 2005). The data
358 presented in this study shows that the HCN channel blocker ZD7288 (1 μ M) reduced the
359 medium AHP by 55-75% in neurons held at -75 mV, confirming deactivation of HCN channel
360 current is a significant component of the medium AHP (Gu et al., 2005; Kaczorowski, 2011).
361 Apamin (100 nM) blocked the medium AHP remaining in ZD7288 (1 μ M), confirming that SK
362 channel activation mediates a significant component of the medium AHP (Stocker et al.,

363 1999; Bond et al., 2004; Kaczorowski et al., 2007; Church et al., 2014). Both SK and HCN
364 channels can be either homomeric or heteromeric. For example, the current underlying the
365 medium AHP is inhibited by apamin with an IC_{50} of 450 pM (Stocker et al., 1999), which is
366 reminiscent of the sensitivity of heteromeric SK1-SK2 channel current to the toxin (Church et
367 al. 2015). Homo- and hetero-tetrameric HCN channels display different electrophysiological
368 and kinetic properties when expressed in heterologous cell lines (Santoro et al., 2000;
369 Robinson and Siegelbaum, 2003; Wahl-Schott and Biel, 2009). The expression of HCN
370 channel subunits varies throughout the brain, with only HCN1 and HCN2 mRNA and protein
371 abundantly expressed in the hippocampus (Santoro et al., 2000). Native H-current is thought
372 to be mediated by a population of heteromeric HCN1-2 and homomeric HCN1 subunit
373 channels because the biophysical properties of H-current recorded in CA1 pyramidal reflect
374 a population of heteromeric HCN1-2 channels and possible HCN1 homomeric channels
375 (Santoro et al. 2000).

376

377 Non-selective actions of ZD7288 have been reported, with T-type calcium channel current
378 blocked with an IC_{50} of 100 μ M (Felix et al., 2003), ionotropic glutamate receptor currents
379 reduced by 40% using 20 μ M ZD7288 (Chen, 2004), and inhibition of sodium channel
380 current in dorsal root ganglion neurons with an IC_{50} close to 10 μ M (Wu et al., 2012). In
381 addition, relatively long-term application of ZD7288 can produce non-selective effects, with
382 application of ZD7288 (30 μ M) producing a significant depression of glutamatergic-mediated
383 synaptic activity at hippocampal mossy fibre synapses (Chevaleyre and Castillo, 2002; Gill et
384 al., 2006). We circumvented the possibility of non-selective effects of ZD7288 by blocking
385 AMPA receptor-mediated synaptic potentials with NBQX, using only 1 μ M of the compound,
386 and finally recording the effect of the HCN channel blocker within 10 minutes of application.
387 Pre-block of HCN channels with ZD7288 reduced suppression of the remaining medium
388 AHP by isoproterenol (Fig. 4Aiii & iv). These data suggest that β 3-adrenergic receptor-
389 mediated suppression of the medium AHP occurs by inhibition of HCN channel activity.
390 HCN channel activation undergoes a depolarizing shift from an increase in the intracellular

391 cAMP concentration (Wainger et al., 2001; Santoro et al., 2004; Chen et al., 2007; Zong et
392 al., 2012)._However, activation of β 3-adrenergic receptors suppresses the medium AHP in
393 neurons dialyzed with cAMP. These data show that modulation of HCN channels is
394 independent of a rise of intracellular cAMP.

395

396 **Do β 3ARs functionally couple with HCN channels?**

397 The medium AHP was retained in cells dialyzed with cAMP. Furthermore, the reduction of
398 the medium AHP by isoproterenol was independent of intracellular cAMP levels. In addition,
399 the medium AHP was reduced in amplitude by the β 3 adrenergic receptor-selective agonist
400 BRL37344, both in control cells and cells dialyzed with cAMP. The isoproterenol- and
401 BRL37344-mediated suppression of the medium AHP in the presence of raised intracellular
402 cAMP indicates that the inhibitory effect on the medium AHP is not mediated by activation of
403 either $G\alpha_s$ - or $G\alpha_i$ G-protein affecting cAMP levels. The β 3-adrenergic receptor signalling
404 pathway is ill-defined, with the receptor being reported to couple to $G\alpha_s$ or $G\alpha_i$ (Collins,
405 2012). Other studies report β 3-adrenergic receptors signal in a biphasic manner by coupling
406 to both $G\alpha_s$ and $G\alpha_i$ (Begin-heick, 1995; Gauthier et al., 1996; Hadi et al., 2013).
407 Regardless of possible second messenger pathways, activation of β 3-adrenergic receptors
408 causes relaxation of rat bladder, an effect blocked by ZD7288. This observation indicates
409 that coupling can occur between activation of β 3-adrenergic receptors and HCN channels
410 (Kashyap et al., 2015). The reported anti-depressant and anti-anxiolytic properties of β 3-
411 adrenergic receptor agonists make this pathway an attractive one to target, with further
412 investigation being needed.

413

414 HCN channels, which underlie H-current, are a key regulator of intrinsic excitability in CA1
415 pyramidal neurons. H-current has a direct influence on neuronal input resistance, the resting
416 membrane potential and membrane time constant. H-current filters out low frequency
417 fluctuations in membrane voltage in a self-regulating feedback mechanism to regulate
418 synaptic input (He et al., 2014). Inhibition of H-current by ZD7288 increased firing frequency

419 in hippocampal neurons (Gasparini & DiFrancesco, 1997), an effect demonstrating the
420 contribution of the H-current to the medium AHP. It is interesting to note that this current can
421 be modulated to affect firing by activation of a receptor that is expressed at low levels in
422 hippocampal neurons. It will be useful to resolve the relative subcellular locations of HCN
423 and β 3-adrenergic receptors in hippocampal neurons to determine if coupling is localized
424 within the cell.

425

426 Afterhyperpolarizations have a profound impact on hippocampal neuronal excitability. Action
427 potential firing frequency increases with inhibition of either the medium (Stocker et al., 1999)
428 or the slow AHP (Madison and Nicoll, 1982, 1986; Pedarzani and Storm, 1993; Pedarzani et
429 al., 1998; Stocker et al., 1999). The amplitude of the AHP is correlated with learning and
430 memory with larger AHPs being observed in aged animals that have difficulty in learning.
431 Pharmacological suppression of the AHP in aged animals improves learning of a simple
432 associative task (Moyer and Disterhoft, 1994; Tombaugh et al., 2005). The identification of a
433 novel mechanism regulating the medium AHP provides additional plasticity to how
434 membrane excitability might change to affect these processes. The identity of functional β 3-
435 adrenergic receptors in hippocampal CA1 neurons highlights a potential new target in
436 modulating HCN channels and thereby synaptic plasticity.

437

438 **References**

- 439 Alger, B.E. and Nicoll, R.A. (1980) Epileptiform burst afterhyperpolarization: calcium-
440 dependent potassium potential in hippocampal CA1 pyramidal cells. *Science* (New York,
441 N.Y.), 210 (4474): 1122–1124
- 442 Alger, B.E. and Williamson, A. (1988) A transient calcium-dependent potassium component
443 of the epileptiform burst after-hyperpolarization in rat hippocampus. *The Journal of*
444 *Physiology*, 399 (1): 191–205
- 445 Begin-heick, N. (1995) Beta3-Adrenergic activation of adenylyl cyclase in mouse white
446 adipocytes: modulation by GTP and effect of obesity. *Journal of Cellular Biochemistry*, (58):
447 464–473
- 448 Bianchetti, A. and Manara, L. (1990) In vitro inhibition of intestinal motility by
449 phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon. *British*
450 *Journal of Pharmacology*, 100 (4): 831–839
- 451 Bond, C.T., Herson, P.S., Strassmaier, T., Hammond, R., Stackman, R., Maylie, J. and
452 Adelman, J.P. (2004) Small conductance calcium-activated potassium channel knock-out
453 mice reveal the identity of calcium-dependent afterhyperpolarization currents. *The Journal of*
454 *Neuroscience*, 24 (23): 5301–2306
- 455 Candelore, M.R., Deng, L., Tota, L., Guan, X.M., Amend, A., Liu, Y., Newbold, R., Cascieri,
456 M.A., Weber, A.E. (1999). Potent and selective human beta(3)-adrenergic receptor
457 antagonists. *J Pharmacol Exp Ther.* 290(2):649-55
- 458 Chen, C. (2004) ZD7288 inhibits postsynaptic glutamate receptor-mediated responses at
459 hippocampal perforant path–granule cell synapses. *European Journal of Neuroscience*, 19
460 (3): 646–649
- 461 Chen, S., Benninger, F. and Yaari, Y. (2014) Role of small conductance calcium-activated
462 K⁺ channels in controlling CA1 pyramidal cell excitability. *The Journal of Neuroscience*, 34
463 (24): 8219–8230
- 464 Chen, S., Wang, J., Zhou, L., George, M.S. and Siegelbaum, S.A. (2007) Voltage sensor
465 movement and cAMP binding allosterically regulate an inherently voltage-independent

466 closed-open transition in HCN channels. *The Journal of General Physiology*, 129 (2): 175–
467 188

468 Chevaleyre, V. and Castillo, P.E. (2002) Assessing the role of Ih channels in synaptic
469 transmission and mossy fiber LTP. *Proceedings of the National Academy of Sciences of the*
470 *United States of America*, 99 (14): 9538–9543

471 Church, T.W., Weatherall, K.L., Corrêa, S. a L., Prole, D.L., Brown, J.T. and Marrion, N. V
472 (2015) Preferential assembly of heteromeric small conductance calcium-activated potassium
473 channels. *The European Journal of Neuroscience*, 41 (3): 305–315

474 Claustre, Y., Leonetti, M., Santucci, V., Bougault, I., Desvignes, C., Rouquier, L., Aubin, N.,
475 Keane, P., Busch, S., Chen, Y., Palejwala, V., Tocci, M., Yamdagni, P., Didier, M., Avenet,
476 P., Le Fur, G., Oury-Donat, F., Scatton, B. and Steinberg, R. (2008) Effects of the beta3-
477 adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic
478 transmission in the rodent: relevance to its antidepressant/anxiolytic-like profile.
479 *Neuroscience*, 156 (2): 353–364

480 Collins, S. (2012) Beta-Adrenoceptor signaling networks in adipocytes for recruiting stored
481 fat and energy expenditure. *Frontiers in Endocrinology*, 2 (102): 1–7

482 Consoli, D., Leggio, G.G.M., Mazzola, C., Micale, V. and Drago, F. (2007) Behavioral effects
483 of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of
484 antidepressant/anxiolytic drugs? *European Journal of Pharmacology*, 573 (1–3): 139–47

485 Cox, D.J., Racca, C. and LeBeau, F.E.N. (2008) Beta-Adrenergic receptors are differentially
486 expressed in distinct interneuron subtypes in the rat hippocampus. *Journal of Comparative*
487 *Neurology*, 509 (6): 551–565

488 Day, M., Carr, D.B., Ulrich, S., Ilijic, E., Tkatch, T. and Surmeier, D.J. (2005) Dendritic
489 excitability of mouse frontal cortex pyramidal neurons is shaped by the interaction among
490 HCN, Kir2, and leak channels. *Journal of Neuroscience*, 25 (38): 8776–8787

491 Evans, B.A., Papaioannou, M., Bonazzi, V.R. and Summers, R.J. (1996) Expression of beta
492 3-adrenoceptor mRNA in rat tissues. *British Journal of Pharmacology*, 117 (1): 210–216

493 Felix, R., Sandoval, A., Sánchez, D., Gómora, J.C., Vega-Beltrán, J.L.D. La, Treviño, C.L.

494 and Darszon, A. (2003) ZD7288 inhibits low-threshold calcium channel activity and regulates
495 sperm function. *Biochemical and Biophysical Research Communications*, 311 (1): 187–192

496 Gauthier, C., Tavernier, G., Charpentier, F., Langin, D. and Le Marec, H. (1996) Functional
497 beta3-adrenoceptor in the human heart. *The Journal of Clinical Investigation*, 98 (2): 556–
498 562

499 Gasparini, S. and DiFrancesco, D. (1997). Action of the hyperpolarization-activated current
500 (I_h) blocker ZD 7288 in hippocampal CA1 neurons. *Pflügers Arch – Eur J Physiol* (1997)
501 435:99–106

502 Gerlach, A.C., Maylie, J. and Adelman, J.P. (2004) Activation kinetics of the slow
503 afterhyperpolarization in hippocampal CA1 neurons. *Pflügers Archiv: European Journal of*
504 *Physiology*, 448 (2): 187–196

505 Gill, C.H., Brown, J.T., Shivji, N., Lappin, S.C., Farmer, C., Randall, A., McNaughton, N.C.L.,
506 Cobb, S.R. and Davies, C.H. (2006) Inhibition of I_h reduces epileptiform activity in rodent
507 hippocampal slices. *Synapse (New York, N.Y.)*, 59 (5): 308–16

508 Gu, N., Hu, H., Vervaeke, K. and Storm, J.F. (2008) SK (KCa2) channels do not control
509 somatic excitability in CA1 pyramidal neurons but can be activated by dendritic excitatory
510 synapses and regulate their impact. *Journal of Neurophysiology*, 100 (5): 2589–604

511 Gu, N., Vervaeke, K., Hu, H. and Storm, J.F. (2005) Kv7/KCNQ/M and HCN/h, but not
512 KCa2/SK channels, contribute to the somatic medium after-hyperpolarization and excitability
513 control in CA1 hippocampal pyramidal cells. *The Journal of Physiology*, 566 (3): 689–715

514 Gullledge, A.T., Dasari, S., Onoue, K., Stephens, E.K., Hasse, J.M. and Avesar, D. (2013) A
515 sodium-pump-mediated afterhyperpolarization in pyramidal neurons. *The Journal of*
516 *Neuroscience*, 33 (32): 13025–13041

517 Guo, N.-N. and Li, B.-M. (2007) Cellular and subcellular distributions of β 1- and β 2-
518 Adrenoceptors in the CA1 and CA3 regions of the rat hippocampus. *Neuroscience*, 146 (1):
519 298–305

520 Haas, H.L. and Greene, R.W. (1986) Effects of histamine on hippocampal pyramidal cells of
521 the rat in vitro. *Experimental brain research. Experimentelle Hirnforschung. Experimentation*

522 cerebrale, 62 (1): 123–130

523 Hadi, T., Barrichon, M., Mourtialon, P., Wendremaire, M., Garrido, C., Sagot, P., Bardou, M.
524 and Lirussi, F. (2013) Biphasic Erk1/2 activation sequentially involving Gs and Gi signaling is
525 required in beta3-adrenergic receptor-induced primary smooth muscle cell proliferation.
526 *Biochimica et Biophysica Acta*, 1833 (5): 1041–1051

527 Hoffmann, C., Leitz, M.R., Oberdorf-Maass, S., Lohse, M.J. and Klotz, K.-N. (2004)
528 Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of
529 stably transfected receptors in CHO cells. *Naunyn-Schmiedeberg's Archives of*
530 *Pharmacology*, 369 (2): 151–159

531 Jhaveri, D.J., Mackay, E.W., Hamlin, A.S., Marathe, S. V, Nandam, L.S., Vaidya, V.A. and
532 Bartlett, P.F. (2010) Norepinephrine directly activates adult hippocampal precursors via
533 beta3-adrenergic receptors. *The Journal of Neuroscience*, 30 (7): 2795–2806

534 Kaczorowski, C.C. (2011) Bidirectional pattern-specific plasticity of the slow
535 afterhyperpolarization in rats: role for high-voltage activated calcium channels and Ih. *The*
536 *European Journal of Neuroscience*, 34 (11): 1756–1765

537 Kaczorowski, C.C., Disterhoft, J. and Spruston, N. (2007) Stability and plasticity of intrinsic
538 membrane properties in hippocampal CA1 pyramidal neurons: effects of internal anions. *The*
539 *Journal of Physiology*, 578 (Pt 3): 799–818

540 Kashyap, M., Yoshimura, N., Smith, P.P., Chancellor, M. and Tyagi, P. (2015)
541 Characterization of the role of HCN channels in β 3-adrenoceptor mediated rat bladder
542 relaxation. *Bladder*, 2 (2): e15

543 King, B., Rizwan, A.P., Asmara, H., Heath, N.C., Engbers, J.D.T., Dykstra, S., Bartoletti,
544 T.M., Hameed, S., Zamponi, G.W. and Turner, R.W. (2015) IKCa channels are a critical
545 determinant of the slow AHP in CA1 pyramidal neurons. *Cell Reports*, 11 (2): 175–182

546 Lancaster, B. and Adams, P.R. (1986) Calcium-dependent current generating the
547 afterhyperpolarization of hippocampal neurons. *Journal of Neurophysiology*, 55 (6): 1268–
548 1282

549 Lancaster, B., Hu, H., Ramakers, G.M.J. and Storm, J.F. (2001) Interaction between

550 synaptic excitation and slow afterhyperpolarization current in rat hippocampal pyramidal
551 cells. *Journal of Physiology*, 536 (3): 809–823

552 Maccaferri, G., Mangoni, M., Lazzari, A. and DiFrancesco, D. (1993) Properties of the
553 hyperpolarization-activated current in rat hippocampal CA1 pyramidal cells Properties of the
554 Hyperpolarization-Activated Hippocampal CA 1 Pyramidal Cells Current in Rat. *Journal of*
555 *Neurophysiology*, 69 (6): 2129–2136

556 Madison, D. V and Nicoll, R.A. (1982) Noradrenaline blocks accommodation of pyramidal
557 cell discharge in the hippocampus. *Nature*, 299 (5884): 636–638

558 Madison, D. V and Nicoll, R.A. (1984) Control of the repetitive discharge of rat CA1
559 pyramidal neurones in vitro. *The Journal of Physiology*, (354): 319–331

560 Madison, D. V and Nicoll, R.A. (1986) Cyclic adenosine 3',5'-monophosphate mediates beta-
561 receptor actions of noradrenaline in rat hippocampal pyramidal cells. *The Journal of*
562 *Physiology*, 372: 245–259

563 Malenka, R.C. and Nicoll, R.A. (1986) Dopamine decreases the calcium-activated
564 afterhyperpolarization in hippocampal CA1 pyramidal cells. *Brain Research*, 379 (2): 210–
565 215

566 Manara, L., Badone, D., Baroni, M., Boccardi, G., Cecchi R., Croci, T., Giudice A., Guzzi, U.,
567 Landi, M. and Le Fur, G. (1996) Functional identification of rat atypical beta-adrenoceptors
568 by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. *Br J Pharmacol.*
569 117(3):435-442.

570 Moyer, J.R. and Disterhoft, J.F. (1994) Nimodipine decreases calcium action potentials in
571 rabbit hippocampal CA1 neurons in an age-dependent and concentration-dependent
572 manner. *Hippocampus*, 4 (1): 11–17

573 Pedarzani, P., Krause, M., Haug, T., Storm, J.F. and Stuhmer, W. (1998) Modulation of the
574 calcium-Activated potassium Current IsAHP by a phosphatase-kinase balance under basal
575 conditions in rat CA1 pyramidal neurons. *Journal of Neurophysiology*, 79 (6): 3252–3256

576 Pedarzani, P., McCutcheon, J.E., Rogge, G., Jensen, B.S., Christophersen, P., Hougaard,
577 C., Strøbaek, D. and Stocker, M. (2005) Specific enhancement of SK channel activity

578 selectively potentiates the afterhyperpolarizing current I(AHP) and modulates the firing
579 properties of hippocampal pyramidal neurons. *The Journal of Biological Chemistry*, 280 (50):
580 41404–41411

581 Pedarzani, P. and Storm, J.F. (1993) PKA mediates the effects of monoamine transmitters
582 on the K⁺ current underlying the slow spike frequency adaptation in hippocampal neurons.
583 *Neuron*, 11 (6): 1023–1035

584 Poolos, N.P., Bullis, J.B. and Roth, M.K. (2006) Modulation of h-channels in hippocampal
585 pyramidal neurons by p38 mitogen-activated protein kinase. *The Journal of Neuroscience*,
586 26 (30): 7995–8003

587 Robinson, R.B. and Siegelbaum, S.A. (2003) Hyperpolarization-activated cation currents:
588 from molecules to physiological function. *Annual Review of Physiology*, 65 (4): 453–480

589 Rodriguez, M., Carillon, C., Coquerel, A., Le Fur, G., Ferrara, P., Caput, D. and Shire, D.
590 (1995) Evidence for the presence of beta 3-adrenergic receptor mRNA in the human brain.
591 *Molecular Brain Research*, 29 (2): 369–375

592 Santoro, B., Chen, S., Luthi, A., Pavlidis, P., Shumyatsky, G.P., Tibbs, G.R. and
593 Siegelbaum, S.A. (2000) Molecular and functional heterogeneity of hyperpolarization-
594 activated pacemaker channels in the mouse CNS. *The Journal of Neuroscience*, 20 (14):
595 5264–5275

596 Santoro, B., Wainger, B.J. and Siegelbaum, S.A. (2004) Regulation of HCN channel surface
597 expression by a novel C-terminal protein-protein interaction. *The Journal of Neuroscience*,
598 24 (47): 10750–10762

599 Simiand, J., Keane, P.E., Guitard, J., Langlois, X., Gonalons, N., Martin, P., Bianchetti, A.,
600 Le Fur, G. and Soubrié, P. (1992) Antidepressant profile in rodents of SR 58611A, a new
601 selective agonist for atypical β -adrenoceptors. *European Journal of Pharmacology*, 219 (2):
602 193–201

603 Stemmelin, J., Cohen, C., Terranova, J.-P.P., Lopez-Grancha, M., Pichat, P., Bergis, O.,
604 Decobert, M., Santucci, V., Françon, D., Alonso, R., Stahl, S.M., Keane, P., Avenet, P.,
605 Scatton, B., le Fur, G., Griebel, G., Francon, D., Alonso, R., Stahl, S.M., Keane, P., Avenet,

606 P., Scatton, B., le Fur, G. and Griebel, G. (2008) Stimulation of the beta3-Adrenoceptor as a
607 novel treatment strategy for anxiety and depressive disorders. *Neuropsychopharmacology*,
608 33 (3): 574–587

609 Stocker, M. (2004) Calcium-activated potassium channels: molecular determinants and
610 function of the SK family. *Nature reviews. Neuroscience*, 5 (10): 758–770

611 Stocker, M., Krause, M. and Pedarzani, P. (1999) An apamin-sensitive calcium activated
612 potassium current in hippocampal pyramidal neurons. *Neurobiology*, 96 (8): 4662–4667

613 Stoppini, L., Buchs, P.-A. and Muller, D. (1991) A simple method for organotypic cultures of
614 nervous tissue. *Journal of Neuroscience Methods*, 37 (2): 173–182

615 Storm, J.F. (1989) An after-hyperpolarization of medium duration in rat hippocampal
616 pyramidal cells. *The Journal of Physiology*, 409: 171–190

617 Storm, J.F. (1990) Potassium currents in hippocampal pyramidal cells. *Progress in Brain*
618 *Research*, 83: 161–87

619 Tamagnini, F., Scullion, S., Brown, J.T. and Randall, A.D. (2015) Intrinsic excitability
620 changes induced by acute treatment of hippocampal CA1 pyramidal neurons with
621 exogenous amyloid β peptide. *Hippocampus* 25: 786-797

622 Tamburella, A., Micale, V., Leggio, G.M. and Drago, F. (2010) The beta3 adrenoceptor
623 agonist, amibegron (SR58611A) counteracts stress-induced behavioral and neurochemical
624 changes. *European Neuropsychopharmacology*, 20 (10): 704–13

625 Tanyeri, P., Buyukokuroglu, M.E., Mutlu, O., Ulak, G., Akar, F.Y., Celikyurt, I.K. and Erden,
626 B.F. (2013) Evidence that the anxiolytic-like effects of the beta3 receptor agonist Amibegron
627 involve serotonergic receptor activity. *Pharmacology, Biochemistry, and Behavior*, 110:
628 27–32

629 Thuault, S.J., Malleret, G., Constantinople, C.M., Nicholls, R., Chen, I., Zhu, J., Panteleyev,
630 A., Vronskaya, S., Nolan, M.F., Bruno, R., Siegelbaum, S.A. and Kandel, E.R. (2013)
631 Prefrontal Cortex HCN1 Channels Enable Intrinsic Persistent Neural Firing and Executive
632 Memory Function. *Journal of Neuroscience*, 33 (34): 13583–13599

633 Tombaugh, G.C., Rowe, W.B. and Rose, G.M. (2005) The slow afterhyperpolarization in

634 hippocampal CA1 neurons covaries with spatial learning ability in aged Fisher 344 rats. The
635 Journal of Neuroscience, 25 (10): 2609–2616

636 Turner, R.W., Asmara, H., Engbers, J.D.T., Miclat, J., Rizwan, A.P., Sahu, G. and Zamponi,
637 G.W. (2016) Assessing the role of IKCa channels in generating the sAHP of CA1
638 hippocampal pyramidal cells. Channels, 10 (4): 313–319

639 Tzingounis, A. V., Kobayashi, M., Takamatsu, K. and Nicoll, R.A. (2007) Hippocalcin gates
640 the calcium activation of the slow afterhyperpolarization in hippocampal pyramidal cells.
641 Neuron, 53 (4): 487–493

642 Vatanparast, J. and Janahmadi, M. (2009) Contribution of apamin-sensitive SK channels to
643 the firing precision but not to the slow afterhyperpolarization and spike frequency adaptation
644 in snail neurons. Brain Research, 1255: 57–66

645 Velumian, A.A., Zhang, L., Pennefather, P. and Carlen, P.L. (1997) Reversible inhibition of
646 I(K), I(AHP), I(h) and I(Ca) currents by internally applied gluconate in rat hippocampal
647 pyramidal neurons. Pflugers Archiv European Journal of Physiology, 433 (3): 343–350

648 Wahl-Schott, C. and Biel, M. (2009) HCN channels: structure, cellular regulation and
649 physiological function. Cellular and Molecular Life Sciences, 66 (3): 470–494

650 Wainger, B.J., DeGennaro, M., Santoro, B., Siegelbaum, S.A. and Tibbs, G.R. (2001)
651 Molecular mechanism of cAMP modulation of HCN pacemaker channels. Nature, 411
652 (6839): 805–810

653 Wu, X., Liao, L., Liu, X., Luo, F., Yang, T. and Li, C. (2012) Is ZD7288 a selective blocker of
654 hyperpolarization-activated cyclic nucleotide-gated channel currents? Channels, 6 (6): 438–
655 442

656 Zhang, L., Weiner, J.L., Valiante, T.A., Velumian, A.A., Watson, P.L., Jahromi, S.S.,
657 Schertzer, S., Pennefather, P. and Carlen, P.L. (1994) Whole-cell recording of the calcium-
658 dependent slow afterhyperpolarization in hippocampal neurones: effects of internally applied
659 anions. Pflügers Archiv : European Journal of Physiology, 426 (3–4): 247–53

660 Zong, X., Eckert, C., Yuan, H., Wahl-Schott, C., Abicht, H., Fang, L., Li, R., Mistrik, P.,
661 Gerstner, A., Much, B., Baumann, L., Michalakis, S., Zeng, R., Chen, Z. and Biel, M. (2005)

662 A novel mechanism of modulation of hyperpolarization-activated cyclic nucleotide-gated
663 channels by Src kinase. *Journal of Biological Chemistry*, 280 (40): 34224–34232

664 Zong, X., Krause, S., Chen, C.-C., Krüger, J., Gruner, C., Cao-Ehlker, X., Fenske, S., Wahl-
665 Schott, C. and Biel, M. (2012) Regulation of hyperpolarization-activated cyclic nucleotide-
666 gated (HCN) channel activity by cCMP. *The Journal of biological chemistry*, 287 (32):
667 26506–12

668 **Figure 1. Isoproterenol suppresses the medium and slow AHPs in hippocampal CA1**
669 **pyramidal neurons.**

670 **A.** Representative membrane voltage traces of the AHP evoked by 15 action potentials
671 elicited by 2 ms current injections delivered at 50 Hz before (control, black) and after the
672 addition of isoproterenol (1 μ M; grey). The action potentials are truncated for clarity.

673 **B.** Evoked medium (mAHP) and slow afterhyperpolarizations (sAHP) plotted on a \log_{10} time
674 scale to illustrate how the mAHP and sAHP were discriminated. The mAHP amplitude was
675 measured from the peak voltage deflection recorded at 0-100 ms post-burst, and the sAHP
676 amplitude was measured as the amplitude at 1 s post-burst.

677 **C.** Diary plot of the amplitude of the medium AHP. Application of isoproterenol (1 μ M)
678 reduced the amplitude of the evoked medium AHP (n=7).

679 **D.** Diary plot of the amplitude of the slow AHP. Application of isoproterenol (1 μ M) largely
680 abolished the amplitude of the evoked slow AHP (n=7).

681 Bar charts depicting the reduction in the amplitudes of the evoked medium (mAHP) (**E**) and
682 slow (sAHP) AHPs (**F**) amplitude by isoproterenol (1 μ M). (n=7, paired two-way Student's *t*-
683 test, ** *P* < 0.01).

684 Bar charts depicting the lack of effect on the amplitudes of the evoked medium (mAHP) (**G**)
685 and slow (sAHP) AHPs (**H**) amplitude by isoproterenol (1 μ M), when applied in the presence
686 of propranolol (10 μ M) (n=4, repeated measures ANOVA, NS *P* > 0.05).

687

688

689 **Figure 2. Suppression of the medium AHP by isoproterenol in cells dialysed with**
690 **cAMP.**

691 **A.** Bar chart showing the amplitude of the slow AHP (sAHP) in control cells (black bars,
692 n=80) and in cells dialysed with cAMP (1 mM) (hollow bars, n=20). The slow AHP was
693 measured after being evoked by 5 to 25 action potentials, with the amplitude of the slow
694 afterpotential increasing with increasing number of action potentials. The slow AHP was
695 occluded in cells dialysed with cAMP (1 mM).

696 **B.** Bar chart showing that dialysis with cAMP (1 mM) (n=20) reduces the amplitude but does
697 not occlude the medium AHP. The medium AHP was measured after being evoked by 5 to
698 25 action potentials, with the amplitude of the medium AHP increasing with increasing
699 number of action potentials in control (black bars, n=80) and in the presence of intracellular
700 cAMP (hollow bars, n=20).

701 **C.** Effect of isoproterenol (1 μ M; grey) on the medium AHP evoked by 15 APs fired at 50
702 Hz. Note the lack of a slow AHP in both control (black) and in the presence of isoproterenol.
703 Action potentials have been truncated for clarity.

704 **D.** Evoked medium (mAHP) displayed on a \log_{10} time scale, showing the lack of a slow
705 AHP. Application of isoproterenol (1 μ M) suppressed the medium AHP (grey trace).

706 **E.** Diary plot of the amplitude of the medium AHP. Application of isoproterenol (1 μ M)
707 suppressed the medium AHP amplitude in cells dialysed with cAMP (1 mM) (n=5).

708 **F.** Bar chart showing the amplitude of the medium AHP in control (black bar) and in the
709 presence of isoproterenol (1 μ M) (hollow bar). Isoproterenol (1 μ M) suppressed the medium
710 AHP in cells dialysed with cAMP (n=5, paired two-way Student's *t*-test, *** $P < 0.001$).

711

712

713 **Figure 3. SK and HCN channels mediate the medium AHP in hippocampal CA1**
714 **pyramidal neurons held at -75 mV.**

715 **A.** Representative membrane voltage traces of AHPs evoked by a train of 15 action
716 potentials fired at 50 Hz in control conditions (black), ZD7288 (1 μ M; dark grey), and apamin
717 (100 nm) + ZD7288 (1 μ M, light grey). Action potentials have been truncated for clarity.

718 **B.** Evoked medium AHP and slow AHP from A displayed on a \log_{10} time scale to illustrate
719 the complete block on the medium AHP following the sequential inhibition of HCN and SK
720 channels by ZD7288 and apamin, respectively.

721 **C.** Diary plot of the amplitude of the medium AHP before and after the sequential addition of
722 ZD7288 (1 μ M) and ZD7288 + apamin (100 nM). Note that the medium AHP is completely
723 inhibited by the combination of channel blockers.

724 **D.** Bar chart illustrating the reduction of the medium AHP by ZD7288 (1 μ M), and ZD7288 +
725 apamin (100 nM), with no effect of either blocker on the amplitude of the slow AHP.

726

727

728 **Figure 4. Block of HCN channels reduces suppression of the medium AHP by**
729 **isoproterenol.**

730 **Ai,** Representative membrane voltage trace of the AHP evoked by a train of 15 action
731 potentials fired at 50 Hz in the absence (black trace) and presence of the H-current blocker
732 ZD7288 (1 μ M, dark grey), and ZD7288 + isoproterenol (1 μ M, light grey). The medium AHP
733 was largely blocked by ZD7288, with the addition of isoproterenol having little effect.

734 **Aii.** Evoked medium (mAHP) and slow (sAHP) AHPs displayed on a \log_{10} time scale,
735 showing the large block of the medium AHP by ZD7288 (dark grey) occluding subsequent
736 suppression by isoproterenol (light grey).

737 **Aiii.** Diary plot of the amplitude of the medium AHP, showing the dominating effect of block
738 of H-current by ZD7288 (1 μ M) and minor effect of subsequent addition of isoproterenol (1
739 μ M).

740 **Aiv.** Bar chart showing the amplitude of the medium AHP, significant block of that amplitude
741 by ZD7288 and minor additional effect of the subsequent addition of isoproterenol.

742 **Bi.** Representative membrane voltage trace of the AHP evoked by a train of 15 action
743 potentials fired at 50 Hz in the absence (black trace) and presence of the SK channel
744 inhibitor apamin (100 nM, dark grey), and apamin + isoproterenol (1 μ M, light grey). Only a
745 small effect of apamin on the medium AHP was observed, with subsequent addition of
746 isoproterenol significantly suppressing both the medium and slow AHPs.

747 **Bii.** Evoked medium (mAHP) and slow (sAHP) AHPs displayed on a \log_{10} time scale,
748 showing the minor block of the medium AHP by apamin (dark grey), with a much greater
749 suppression of both the medium and slow AHPs by subsequent addition of isoproterenol
750 (light grey).

751 **Biii.** Diary plot of the amplitude of the medium AHP, showing the minor block by apamin
752 (100 nM) and the significant suppression produced by the subsequent addition of
753 isoproterenol (1 μ M).

754 **Biv.** Bar chart showing the amplitude of the medium AHP. Addition of apamin (100 nM)
755 blocked only a small component of the medium AHP, with a much greater suppression
756 observed on the subsequent addition of isoproterenol.

757
758

759 **Figure 5. β_3 adrenergic receptor activation suppresses the medium AHP.**

760 **Ai.** Representative membrane voltage trace of AHPs evoked by a train of 15 action
761 potentials fired at 50 Hz in the absence (black) and presence of the β_3 AR selective agonist
762 BRL37344 (10 μ M; grey).

763 **Aii.** Evoked medium AHP and slow AHP from **Ai** displayed on a \log_{10} time scale to illustrate
764 a reduction in the medium and slow AHPs by addition of BRL37344 (10 μ M).

765 **Aiii.** Bar chart showing suppression of both AHP components by BRL37344 (10 μ M) (n=4;
766 paired two-tailed Student's t-test).

767 **Bi.** Representative membrane voltage trace of AHPs evoked by a train of 15 action
768 potentials fired at 50 Hz in the absence (black) and presence of the β_3 AR selective agonist

769 SR58611A (10 μ M; grey) in CA1 pyramidal neurons. Action potentials were truncated for
770 clarity.

771 **Bii.** Evoked medium AHP and slow AHP from **Bi** displayed on a \log_{10} time scale to illustrate
772 a reduction in the medium AHP by addition of SR58611A (10 μ M). Note the lack of effect of
773 the β 3-adrenergic receptor agonist on the slow AHP (see Discussion).

774 **Biii.** Bar chart showing suppression of both AHP components by SR58611A/BRL37344 (10
775 μ M) ($n=7$; paired two-tailed Student's t-test).

776 **C.** Diary plot of the amplitude of the medium AHP and the lack of effect of addition of
777 BRL37344 (10 μ M) in the continued presence of propranolol (10 μ M).

778 **D.** Bar chart showing the amplitude of the medium AHP in control conditions, after 10
779 minute incubation with propranolol (10 μ M), and after addition of BRL37344 (10 μ M) in the
780 continued presence of propranolol.

781 **E.** Evoked mAHP and sAHP plotted on a \log_{10} time scale from a cell dialyzed with cAMP (1
782 mM)(black trace). Addition of BRL37344 (10 μ M) suppressed the mAHP in cAMP-dialyzed
783 cells (grey trace).

784 **F.** Summary bar chart showing small but robust block of the mAHP by BRL37344 (10 μ M)
785 ($n = 9$, paired two-tailed Student's t-test).




Figure 1
Church et al




Figure 2
Church et al




Figure 3
Church et al




Figure 4
Church et al




Figure 5
Church et al